Qiagen (NYSE:QGEN) Given New $45.00 Price Target at Stifel Nicolaus

Qiagen (NYSE:QGEN) had its price target decreased by equities research analysts at Stifel Nicolaus from $55.00 to $45.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has a “hold” rating on the stock. Stifel Nicolaus’ price target indicates a potential upside of 5.41% from the stock’s previous close.

QGEN has been the subject of a number of other reports. Morgan Stanley upgraded shares of Qiagen from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $49.48 to $51.00 in a report on Friday, February 16th. JPMorgan Chase & Co. upped their price objective on shares of Qiagen from $50.00 to $52.00 and gave the company an “overweight” rating in a report on Thursday, February 8th. Finally, Citigroup cut their price objective on shares of Qiagen from $61.86 to $60.00 and set a “buy” rating on the stock in a report on Thursday, February 8th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.95.

Qiagen Stock Performance

Shares of Qiagen stock opened at $42.69 on Wednesday. The company has a market capitalization of $9.74 billion, a PE ratio of 28.63, a P/E/G ratio of 3.62 and a beta of 0.42. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.62 and a current ratio of 1.99. The company has a 50-day simple moving average of $42.54 and a two-hundred day simple moving average of $42.71. Qiagen has a one year low of $34.74 and a one year high of $47.70.

Qiagen (NYSE:QGEN) last announced its earnings results on Monday, April 29th. The company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. The business had revenue of $459.00 million during the quarter, compared to the consensus estimate of $453.91 million. Qiagen had a net margin of 17.38% and a return on equity of 12.50%. The firm’s revenue was down 5.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.53 earnings per share. Research analysts expect that Qiagen will post 2.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Qiagen

A number of large investors have recently bought and sold shares of the company. Norges Bank purchased a new stake in Qiagen in the 4th quarter worth approximately $264,322,000. Wellington Management Group LLP increased its stake in shares of Qiagen by 81.0% in the 3rd quarter. Wellington Management Group LLP now owns 6,054,116 shares of the company’s stock worth $245,299,000 after acquiring an additional 2,709,030 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Qiagen by 8.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 24,066,569 shares of the company’s stock worth $1,045,211,000 after acquiring an additional 1,809,486 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Qiagen by 33,220.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,345,488 shares of the company’s stock worth $58,435,000 after purchasing an additional 1,341,450 shares during the last quarter. Finally, Nuance Investments LLC acquired a new stake in shares of Qiagen during the 4th quarter worth about $47,479,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.